Home › Funds › Eversept Partners, LP › DFTX
Eversept Partners, LP position in DFTX
DEFINIUM THERAPEUTICS INC · Health Care
Eversept Partners, LP reported holding 217,185 shares of DFTX (DEFINIUM THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$10.2M, representing 0.53% of its reported portfolio and ranking #48 among its reported holdings. Eversept Partners, LP has disclosed DFTX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Eversept Partners, LP's DFTX position evolved
Eversept Partners, LP first disclosed a stake in DFTX in Q1 2026 at 160,723 shares (US$3.0M). The position peaked in Q2 2026 at 217,185 shares, worth US$10.2M. Across 2 filings, Eversept Partners, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 217,185 shares valued at US$10.2M — an increase of 56,462 shares quarter over quarter.. Notable position changes include a 35% increase in Q2 2026 (shares fell 19% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 160.72K | $3.04M | New |
| Q2 2026 | 217.19K | $10.22M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DFTX and 13F data
DFTX (DEFINIUM THERAPEUTICS INC) is a Health Care company. 189 other funds we track also report a position in DFTX — the largest reported positions include Avoro Capital Advisors LLC (US$338.2M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$322.0M), Octagon Capital Advisors LP (US$138.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DFTX
- Avoro Capital Advisors LLC 7.19M sh · $338.17M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.85M sh · $322.00M · Q2 2026
- Octagon Capital Advisors LP 2.95M sh · $138.77M · Q2 2026
- Deep Track Capital, LP 2.75M sh · $129.36M · Q2 2026
- Commodore Capital LP 2.00M sh · $94.08M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.50M sh · $70.56M · Q2 2026
- Siren, L.L.C. 1.42M sh · $66.77M · Q2 2026
- Boxer Capital Management, LLC 998.50K sh · $46.97M · Q2 2026
- AWM Investment Company, Inc. 784.80K sh · $36.92M · Q2 2026
- ArrowMark Colorado Holdings LLC 564.07K sh · $26.53M · Q2 2026
- Catalio Capital Management, LP 562.67K sh · $26.47M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $25.87M · Q2 2026
More on Eversept Partners, LP
FAQ
How long has Eversept Partners, LP held DFTX?
Eversept Partners, LP has disclosed DFTX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Eversept Partners, LP's current position in DFTX?
As of Q2 2026, Eversept Partners, LP holds 217.19K shares of DFTX (DEFINIUM THERAPEUTICS INC), valued at $10.22M, representing 0.53% of its reported portfolio and ranking #48.
Has Eversept Partners, LP been buying or selling DFTX?
In the latest 13F filing (Q2 2026), Eversept Partners, LP increased its position in DFTX. The position peaked in Q2 2026 at 217.19K shares.
Which other funds hold DFTX?
Other major institutional holders of DFTX include Avoro Capital Advisors LLC, DRIEHAUS CAPITAL MANAGEMENT LLC, Octagon Capital Advisors LP, among 189 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.